Nerve growth factor: From animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease

Progress in Brain Research

Volumn 146, Issue , 2004, Pages 439-449

  Tuszynski, Mark H ^a,b   Blesch, Armin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Gene theraphy; Growth factors; Huntington's disease; Neurodegeneration; Neurological disease; Parkinson's disease

Indexed keywords

CHOLINESTERASE INHIBITOR; DOXYCYCLINE; ECDYSONE; NERVE GROWTH FACTOR; RAPAMYCIN; RETROVIRUS VECTOR; TETRACYCLINE;

ALZHEIMER DISEASE; BRAIN REGION; CELL MIGRATION; CELL PROLIFERATION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; INJECTION PAIN; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NERVE CELL DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OLIVARY NUCLEUS; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT REDUCTION;

EID: 0347479327     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0079-6123(03)46028-7     Document Type: Conference Paper

References (52)

1. Bartus, R., Dean, R.L., Beer, C. and Lippa, A.S. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science, 217: 408-417.
2. Bjorklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C. and Mandel, R.J. (2000) Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res., 886: 82-98.
3. Blesch, A., Conner, J.M. and Tuszynski, M.H. (2001) Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression. Gene Ther., 8: 954-960.
4. Blommer, U., Kafri, T., Randolph-Moore, L., Verma, I.M. and Gage, F.H. (1998) Bel-x1 protects adult septal cholinergic neurons from axotomized cell death. PNAS, 95: 2603-2608.
5. Candy, J.M., Perry, R.H., Perry, E.K., Irving, D., Blessed, G., Fairbairn, A.F. and Tomlinson, B.E. (1983) Pathological changes in the nucleus basalis of Meynert in Alzheimer's and Parkinson's diseases. J. Neurosci., 54: 277-289.
6. Chen, K.S. and Gage, F.H. (1995) Somatic gene transfer of NGF to the aged brain: Behavioral and morphological amelioration. J. Neurosci., 15: 2819-2825.
7. Conner, J.M., Darracq, M.A., Roberts, J. and Tuszynski, M.H. (2001) Non-tropic actions of neurotrophins: Subcortical NGF gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc. Nat. Acad. Sci. USA, 98: 1941-1946.
8. Connor, B., Kozlowski, D.A., Schallert, T., Tillerson, J.L., Davidson, B.L. and Bohn, M.C. (1999) Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther., 6: 1936-1951.
9. Coyle, J.T., Price, P.H. and Delong, M.R. (1983) Alzheimer's disease: A disorder of cortical cholinergic innervation. Science, 219: 1184-1189.
10. Crutcher, K.A. (1987) Sympathetic sprouting in the central nervous system: A model for studies of axonal growth in the mature mammalian brain. Brain Res. Rev., 12: 203-233.
11. Dekker, A.J., Langdon, D.J., Gage, F.H. and Thal, L.J. (1991) NGF increases cortical acetylcholine release in rats with lesions of the nucleus basalis. Neuroreport, 2: 577-580.
12. Emerich, D.F., Lindner, M.D., Winn, S.R., Chen, E.Y., Frydel, B.R. and Kordower, J.H. (1996) Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci., 16: 5168-5181.
13. Emerich, D.F., Winn, S.R., Hantraye, P.M., Peschanski, M., Chen, E.Y., Chu, Y., McDermott, P., Baetge, E.E. and Kordower, J.H. (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature, 386: 395-399.
14. Eriksdotter Jonhagen, M., Nordberg, A., Amberla, K., Backman, L., Ebendal, T., Meyerson, B., Olson, L., Seiger, Shigeta, M., Theodorsson, E., Viitanen, M., Winblad, B. and Wahlund, L.O. (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease, Dement. Geriatr. Cogn. Disord., 9: 246-257.
15. Everitt, B.J. and Robbins, T.W. (1997) Central cholinergic systems and cognition. Ann. Rev. Pscyhol., 48: 649-684.
16. Favre, D., Blouin, V., Provost, N., Spisek, R., Porrot, F., Bohl, D., Marme, F., Cherel, Y., Salvetti, A., Hurtrel, B., Heard, J.M., Riviere, Y. and Moullier, P. (2002) Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol., 76: 11605-11611.
17. Fischer, W., Wictorin, K., Bjorklund, A., Williams, L.R., Varon, S. and Gage, F.H. (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature, 329: 65-68.
18. Frim, D.M., Uhler, T.A., Short, M.P., Ezzedine, Z.D., Klagsbrun, M., Breakefield, X.O. and Isacson, O. (1993) Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport, 4: 367-370.
19. Gash, D.M., Zhang, Z., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J., Gerhardt, G.A. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature, 380: 252-255.
20. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K.O., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P. (2003) Direct infusion of glial cell line-derived neurotrophic factor in Parkinson disease, Nat. Med., 9: 589-595.
21. Gossen, M., Bonin, A.L., Freundlieb, S. and Bujard, H. (1994) Inducible gene expression systems for higher eukaryotic cells. Curr. Opin. Biotechnol., 5: 516-520.
22. Grill, R., Murai, K., Blesch, A., Gage, F.H. and Tuszynski, M.H. (1997) Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J. Neurosci., 17: 5560-5572.
23. Group, A.-C.T.S. (1996) A double-blind placebo-controlled trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology, 46: 1244-1249.
24. Group, T.B.S. (1999) A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology, 52: 1427-1433.
25. Hefti, F. (1986) Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transection. J. Neurosci., 6: 2155-2162.
26. Hyman, C., Hofer, M., Juhasz, M., Yancopoulos, G.P., Squinto, S.P. and Lindsay, R.M. (1994) Brain derived neurotrophic factor is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 350: 230-232.
27. Koliatsos, V.E., Nauta, H.J., Clatterbuck, R.E., Holtzman, D.M., Mobley, W.C. and Price, D.L. (1990) Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey. J. Neurosci., 10: 3801-3813.
28. Kordower, J.H., Winn, S.R., Liu, Y.-T., Mufson, E.J., Sladek, J.R., Hammang, J.P., Baetge, E.E. and Emerich, D.F. (1994) The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc. Nat. Acad. Sci. USA., 91: 10898-10902.
29. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Déglon, N. and Aebischer, P. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290: 767-773.
30. Korsching, S., Auburger, G., Heumann, R., Scott, J. and Thoenen, H. (1985) Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO. J., 4: 1389-1393.
31. Kotzbauer, P.T., Lampe, P.A., Heuckeroth, R.O., Golden, J.P., Creedon, D.J., Johnson, E.M. and Milbrandt, J. (1996) Neurturin, a relative of glial-cell-line derived neurotrophic factor. Nature, 384: 467-470.
32. Lin, L.F., Doherty, D.H., Lile, J.D., Bektesh, S. and Collins, F. (1993) GDNF: A glial cell-line derived neurotrophic factor for midbrain dopaminergic neurons. Science, 260: 1130-1132.
33. Liu, Y., Kim, D., Himes, B.T., Chow, S.Y., Schallert, T., Murray, M., Tessler, A. and Fischer, I. (1999) Transplants of fibroblasts genetically modified to express BDNF promote regeneration of adult rat rubrospinal axons and recovery of forelimb function. J. Neurosci., 19: 4370-4387.
34. Mandel, R.J., Gage, F.H., Clevenger, S.K., Snyder, R.O. and Leff, S.E. (1999) Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp. Neurol., 155: 59-64.
35. Nutt, J.G., Burchiel, K.J., Comella, C.L., Jankovic, J., et al. (2003) Randomized, double-blind trial of glial cell line-derived neurotorphic factor (GDNF) in PD. Neurology, 60: 69-73.
36. Perry, E.K., Perry, R.H., Blessed, G. and Tomlinson, B.E. (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet, 2: 143.
37. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H. and Perry, R.H. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Brit. Med. J., 2: 1457-1459.
38. Rosenberg, M.B., Friedmann, T., Robertson, R.C., Tuszynski, M., Wolff, J.A., Breakefield, X.O. and Gage, F.H. (1988) Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science, 242: 1575-1578.
39. Smith, D.E., Roberts, J., Gage, F.H. and Tuszynski, M.H. (1999) Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc. Nat. Acad. Sci. USA, 96: 10893-10898.
40. Spina, M.B., Hyman, C., Squinto, S. and Lindsay, R.M. (1992) Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Ann. N.Y. Acad. Sci., 648: 348-350.
41. Suhr, S.T., Gil, E.B., Senut, M.C. and Gage, F.H. (1998) High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc. Natl. Acad. Sci. USA, 95: 7999-8004.
42. Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A. and Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 30: 572-580.
43. Tuszynski, M.H., U, H.S., Amaral, D.G. and Gage, F.H. (1990) Nerve growth factor infusion in primate brain reduces lesion-induced cholinergic neuronal degeneration, J. Neurosci., 10: 3604-3614.
44. Tuszynski. M.H., Roberts, J., Senut, M.C., U, H.-S. and Gage, F.H. (1996) Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther., 3: 305-314.
45. Tuszynski, M.H., Grill, R., Jones, L., McKay, H.M. and Belsch, A. (2002) Spontaneous and augmented growth of axons in the primate spinal cord: Effects of local injury and nerve growth factor-secreting cells. J. Comp. Neurol., 448: 88-101.
46. Voytko, M.L., Olton, D.S., Richardson, R.T., Gorman, L.K., Tobin, J.R. and Price, D.L. (1994) Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J. Neurosci., 14: 167-186.
47. Whitehouse, P.J., Price, D.J., Clark, A., Coyle, J.T. and DeLong, M. (1981) Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol., 10: 122-126.
48. Whitehouse, P.J., Price, D.L., Struble, R.G., Clar, A.W., Coyle, J.T. and Delong, M.R. (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science, 215: 1237-1239.
49. Williams, L.R. (1991) Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp. Neurol., 113: 31-37.
50. Winkler, C., Sauer, H., Lee, C.S. and Bjorklund, A. (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci., 16: 7206-7215.
51. Winkler, J., Ramirez, G.A., Kuhn, H.G., Peterson, D.A., Day-Lollini, P.A., Stewart, G.R., Tuszynski, M.H., Gage, F.H. and Thal, L.J. (1997) Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol., 41: 82-93.
52. Ye, X., Rivera, V.M., Zoltick, P., Cerasoli, F., Schnell, M.A., Gao, G., Hughes, J.V., Gilman, M. and Wilson, J.M. (1999) Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science, 283: 88-91.